Clinical Trial Update: 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 68Ga-PSMA-11 PET/CT screening before Lu-177-PSMA-617 therapy in metastatic castration-resistant prostate cancer has completed and poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Stage Ivb Prostate Cancer Ajcc V8

Drugs mentioned

• Ga-68 PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical imaging agent)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Mayo Clinic | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2025-07-09